Here are some of the companies saying weight loss drugs could impact their business

The impact of new weight loss treatments is being felt well beyond the health-care industry . Analysts used the ritual of quarterly earnings calls to probe companies on whether their businesses were being helped — or hampered by — the latest trend. Drugs that mimic gut hormones like glucagon-like peptide-1, or GLP-1, were first used to treat diabetes, but have gained favor as obesity treatments.

Cardinal Health also said the medications provided a tailwind to its revenue for another quarter. The company raised its fiscal 2024 pharmaceutical sales outlook, citing help from the drugs. Employers watch health-care costs More than 40% of the U.S. adult population is considered obese, and some worry health-care costs will rise rapidly as the drugs become widely used. Some companies already bar weight loss medications from their insurance plans to keep costs down.

대한민국 최근 뉴스, 대한민국 헤드 라인

Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.

CNBC Daily Open: Treasury yields are putting pressure on stocksRising U.S. Treasury yields are straining stocks. And with rates possibly going higher if inflation resurges, yields could climb further still.
출처: nbcchicago - 🏆 545. / 51 더 많은 것을 읽으십시오 »

CNBC Daily Open: Stocks are under pressure from Treasury yieldsRising U.S. Treasury yields are straining stocks. And with rates possibly going higher if inflation resurges, yields could climb further still.
출처: CNBC - 🏆 12. / 72 더 많은 것을 읽으십시오 »

Wall Street's official stock market outlook — The latest CNBC Market Strategist SurveyWhere do the sharpest minds on Wall Street believe the market is headed? The CNBC PRO exclusive Market Strategist Survey is a roundup of year-end targets for the S&P 500.
출처: CNBC - 🏆 12. / 72 더 많은 것을 읽으십시오 »